Skip to content

Feasibility of Tracheobronchial Reconstruction Using Allogenic Aortic Patch in Children

Feasibility of Tracheobronchial Reconstruction Using Allogenic Aortic Patch in Children

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07240259
Enrollment
5
Registered
2025-11-20
Start date
2026-12-01
Completion date
2028-01-31
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Disease, Trachea Diseases, Tracheal Reconstruction Surgery, Tracheal Stenosis, Tracheal Stenosis Following Tracheostomy, Tracheomalacia, Tuberculosis; Tracheitis

Keywords

tracheomalacia, bronchial reconstruction, cryopreserved aorta, tracheal reconstruction, tracheal stenosis

Brief summary

Feasibility and safety of repairing tracheal and bronchial defects in infants and children using cryopreserved donor aortic patches.

Detailed description

This trial plans to use cryopreserved donor aortic tissue patches to repair and treat pediatric patients with end-stage, life-threatening or severely disabling tracheal diseases who have not responded to conventional conservative therapies or lack sufficient native tracheal tissue for tracheal defect reconstruction.

Interventions

After resection of the tracheal or bronchial lesion with standard surgical techniques, the airway gap is reconstructed with a segment of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

Meeting any of the following conditions, and being unsuitable for standard end-to-end tracheal anastomosis or lacking sufficient native tracheal tissue for defect reconstruction: 1. Congenital tracheal malformations: including congenital tracheomalacia, congenital tracheobronchial anomalies, complete tracheal rings, etc., with severe clinical respiratory symptoms and recommended for treatment after evaluation. 2. Acquired tracheal stenosis: including tracheal narrowing caused by disease, endotracheal intubation, or postoperative scar formation, with severe clinical respiratory symptoms and recommended for treatment after evaluation. 3. Tracheal injury or tissue loss due to trauma or burns requiring surgical repair. 4. Tracheal tumors: reconstruction of tracheal tissue after resection of benign or malignant tumors. 5. The term "severe clinical respiratory symptoms" includes: 1. Dependence on mechanical ventilation for more than 1 month due to airway narrowing or defect, with inability to wean. 2. Airway stenosis exceeding 50% (confirmed by bronchoscopy or CT imaging), accompanied by persistent stridor, inspiratory dyspnea, or suprasternal/substernal retractions, causing impairment of daily activities or feeding difficulties. 3. Unilateral or bilateral lung atelectasis persisting for more than 1 month due to tracheal or bronchial stenosis, with no sign of recovery. 4. Recurrent post-obstructive pneumonia (≥3 episodes) in one or both lungs caused by tracheal or bronchial stenosis, requiring hospitalization for treatment.

Exclusion criteria

1. Inability to obtain legal informed consent from the lawful guardian. 2. Locally invasive tracheal tumors that cannot be completely resected surgically. 3. Malignant solid tumors with distant metastases that cannot be completely resected surgically or controlled with medication. 4. Presence of severe immunodeficiency (e.g., congenital immunodeficiency, HIV infection, ongoing chemotherapy, or recovery period after bone marrow transplantation). 5. Presence of major congenital diseases or chromosomal abnormalities (e.g., Trisomy 13, Trisomy 18) with extremely poor prognosis as assessed clinically. 6. End-stage organ failure (e.g., persistent multiple organ failure, irreversible cardiopulmonary failure, or brain death).

Design outcomes

Primary

MeasureTime frameDescription
90-day MortalityPostoperative 90 daysSurvival status of patients within 90 days after surgery. This primary endpoint evaluates patient mortality, as patients undergoing this type of surgery often have a high short-term risk of death.

Secondary

MeasureTime frameDescription
Anastomotic LeakageWithin 90 days postoperativelyIncidence of anastomotic leakage at the tracheal anastomosis site.
PneumoniaWithin 90 days postoperativelyIncidence of postoperative pneumonia.
Difficult ExtubationWithin 90 days postoperativelyOccurrence of difficulties in extubation after surgery.
Granulation Tissue ObstructionWithin 90 days postoperativelyIncidence of airway obstruction due to granulation tissue formation.
Stenosis Caused by Scar Fibrosis and Related ComplicationsWithin 90 days postoperativelyOccurrence of airway stenosis due to scar fibrosis or other related complications.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026